The evidence for the use of growth factors and active skin substitutes for the treatment of non-infected diabetic foot ulcers (DFU): A health technology assessment (HTA)

Experimental and Clinical Endocrinology and Diabetes

Volumn 119, Issue 8, 2011, Pages 472-479

  Buchberger, B ^a   Follmann, M ^b   Freyer, D ^a   Huppertz, H ^a   Ehm, A ^a   Wasem, J ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b German Cancer Society   (Germany)

Author keywords

diabetic foot; growth factors; ulcer; wound healing

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BECAPLERMIN; CARBOXYMETHYLCELLULOSE; GROWTH FACTOR; RECOMBINANT EPIDERMAL GROWTH FACTOR;

CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DIABETIC FOOT; DRUG EFFICACY; DRUG SAFETY; ECONOMIC ASPECT; ETHICS; EXTRACELLULAR MATRIX; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; SKIN GRAFT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; WOUND CARE; WOUND CLOSURE; WOUND HEALING;

COMBINED MODALITY THERAPY; DIABETIC FOOT; EPIDERMAL GROWTH FACTOR; EVIDENCE-BASED MEDICINE; FIBROBLAST GROWTH FACTORS; HUMANS; PLATELET-DERIVED GROWTH FACTOR; RECOMBINANT PROTEINS; SKIN, ARTIFICIAL; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 80052668017     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0031-1279713     Document Type: Review

References (39)

1. Wild S, Roglic G, Green A et al,. Prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004 27 10 1047-1053 (Pubitemid 38579764)
2. Bakker K, Riley P. The year of the diabetic foot. DiabetesVoice 2005 50 1 11-14
3. World Health Organization WHO. World Diabetes Day: too many people are losing lower limbs unnecessarily to diabetes [cited 2010 Apr 15]. Available from http://www.who.int/mediacentre/news/releases/2005/pr61/en/index.html 2010
4. Buchberger B, Follmann M, Freyer D et al,. Bedeutung von Wachstumsfaktoren für die Behandlung von chronischen Wunden am Beispiel des diabetischen Fußulcus. Köln: DAHTA@DIMDI; Available from http://portal.dimdi.de/de/hta/hta-berichte/hta262-bericht-de.pdf 2010
5. Moher D, Schulz KF, Altman DG, for the CONSORT group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001 357 1191-1194 (Pubitemid 32378696)
6. Siebert U, Behrend C, Mühlberger N et al,. Entwicklung eines Kriterienkataloges zur Beschreibung und Bewertung ökonomischer Evaluationsstudien in Deutschland. In: Leidl R, Schulenburg JM Graf von der, Wasem J (eds). Ansätze und Methoden der ökonomischen Evaluation eine internationale Perspektive. Health Technology Assessment, Bd. 9. Baden-Baden Nomos 1999 156-170
7. Marston WA, Hanft J, Norwood P, et al for the Dermagraft Diabetic Foot Ulcer Study Group. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers. Results of a prospective randomized trial. Diabetes Care 2003 26 1701-1705 (Pubitemid 36929107)
8. Edmonds M, European and Australian Apligraf Diabetic Foot Ulcer Study Group. Apligraf in the treatment of neuropathic diabetic foot ulcers. Int J Low Extrem Wounds 2009 8 1 11-18
9. Bhansali A, Venkatesh S, Dutta P et al,. Which is the better option: recombinant human PDGF-BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off-loaded by a customized contact cast? Diabetes Res Clin Pract 2009 83 1 e13-e16
10. dHemecourt PA, Smiell JA, Karim MR. Sodium Carboxymethylcellulose Aqueous-Based Gel vs. Becaplermin Gel in Patients with Nonhealing Lower Extremity Diabetic Ulcers. Wounds 1998 10 3 69-75
11. Hardikar JV, Chiranyeev Reddy Y, Deen Dayal Bung. et al and the HEALACE Study Group Efficacy of recombinant human platelet-derived growth factor (rhPDGF) based Gel in diabetic foot ulcers: A randomized, multicenter, double-blind, placebo-controlled study in India. Wounds 2005 17 6 141-152 (Pubitemid 40992958)
12. Steed and the Diabetic Ulcer Study Group. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg 1995 21 1 71-81
13. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (Becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 1998 21 5 822-827 (Pubitemid 28487079)
14. Niezgoda JA, Van Gils CC, Frykberg RG, et al and the Oasis Diabetic Ulcer Study Group. Randomized clinical trial comparing Oasis wound matrix to Regranex gel for diabetic ulcers. Adv Skin Wound Care 2005 18 5 258-266
15. Tsang MW, Wong WKR, Hung CS et al,. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care 2003 26 6 1856-1861 (Pubitemid 36929133)
16. TM 150) in healing diabetic foot ulcers. Wounds 2006 18 7 186-196 (Pubitemid 44338024)
17. Richard JL, Parer-Richard C, Daures JP et al,. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study. Diabetes Care 1995 18 1 64-69
18. Gentzkow GD, Iwasaki SD, Hershon KS et al,. Use of Dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996 19 4 350-354 (Pubitemid 26115458)
19. Hanft JR, Surprenant MS. Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis. J Foot Ankle Surg 2002 41 5 291-299 (Pubitemid 35176267)
20. Pollak RA, Edington H, Jensen JL. et al and the Dermagraft Diabetic Ulcer Study Group A human dermal replacement for the treatment of diabetic foot ulcers. Wounds 1997 9 6 175-183 (Pubitemid 127580015)
21. Robson MC, Payne WG, Garner WL et al,. Integrating the results of phase IV (postmarketing) clinical trial with four previous trials reinforces the position that Regranex (becaplermin) Gel 0.01% is an effective adjunct to the treatment of diabetic foot ulcers. J Appl Res 2005 5 1 35-45
22. Smiell JM, Wieman TJ, Steed DL et al,. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair 1999 7 5 335-346 (Pubitemid 29523009)
23. Ghatnekar O, Persson U, Willis M et al,. The cost-effectiveness in the UK of treating diabetic lower extremity ulcers with becaplermin gel. J Drug Asses 2000 3 243-251
24. Ghatnekar O, Persson U, Willis M et al,. Cost Effectiveness of Becaplermin in the Treatment of Diabetic Foot Ulcers in Four European Countries. Pharmacoeconomics 2001 19 7 767-778 (Pubitemid 32664733)
25. Kantor J, Margolis DJ. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis (Structured abstract). Dermatol Surg 2001 27 4 347-351 (Pubitemid 32290859)
26. Persson U, Willis M, Ödegaard K et al,. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data (Structured abstract). Value in Health 2000 3 39-46
27. Sibbald RG, Torrance G, Hux M et al,. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers. Ostomy Wound Manage 2003 49 11 76-84
28. Allenet B, Parée F, Lebrun T et al,. Cost-effectiveness modeling of Dermagraft for the treatment of diabetic foot ulcers in the French context. Diabetes Metab 2000 26 2 125-132 (Pubitemid 30307584)
29. Segal L, John S. The use of dermagraft in neuropathic foot ulcers in people with diabetes: an economic analysis in Australia. Primary Intention 10 2 49-57
30. Redekop WK, McDonnell J, Verboom P et al,. The cost effectiveness of Apligraf treatment of diabetic foot ulcers. Pharmacoeconomics 2003 21 16 1171-1183 (Pubitemid 37463826)
31. Steinberg J, Beusterien K, Plante K et al,. A cost analysis of a living skin equivalent in the treatment of diabetic foot ulcers. Wounds 2002 14 142-149 (Pubitemid 41505206)
32. Roehrig B, du Prel J-B, Blettner M. Studiendesign in der medizinischen Forschung Teil 2 der Serie zur Bewertung wissenschaftlicher Publikationen. Dtsch Arztebl Int 2009 106 11 184-189
33. Schulz KF, Grimes DA. Blinding in randomised trials: hiding who got what. Lancet 2002 359 696-700 (Pubitemid 34203775)
34. Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet 2002 359 614-618 (Pubitemid 34178448)
35. Higgins JPT, Green S. eds Assessment of study quality. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated 2006 September; cited 2010 Jan 05], section 6. Available from: http://www.cochrane.org/sites/default/ files/uploads/Handbook4.2.6Sep2006.pdf 2006
36. Steed DL. Clinical Evaluation of Recombinant Human Platelet-Derived Growth Factor for the Treatment of Lower Extremity Ulcers. Plastic and Reconstructive Surgery 2006 117 7S 143-149 7181
37. Steed DL, Donohoe D, Webster MW, et al and the Diabetic Ulcer Study Group. Effect of extensive Debridement and Treatment on the Healing of Diabetic Foot Ulcers. J Am Coll Surg 1996 183 61-64 (Pubitemid 26234895)
38. Hinchliffe RJ, Valk GD, Apelqvist J et al,. A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab Res Rev 2008 24 S119-S144 (Pubitemid 351802785)
39. Higgins J, Altmann DG. Assessing risk of bias in included studies. In: Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.0.0. Oxford, UK The Cochrane Collaboration 2008